The company also announced the formation of its Clinical Advisory Board, which will work closely with Dr. Genge on QurAlis’ clinical research and development programs in ALS and frontotemporal dementia (FTD) as the company prepares to move its pipeline to the clinical stage....
Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced the appointment of Rupert Sandbrink, M.D., Ph.D., as the company’s chief medical officer and Anders Hinsby, Ph.D., as independent Director....
Dr. Zinkewich-Péotti brings strong R&D leadership experience from both international biopharmaceutical companies and smaller biotech. Over the course of her career she has developed extensive expertise in different therapeutic modalities, including antibodies, antibody-drug conjugates and small molecules....
Accent Therapeutics is been named by Fierce Biotech as one of 2020’s Fierce 15, one of the most promising private biotechnology companies in the industry....
Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced today the appointment of Julie Hambleton, M.D., to its board of directors. Dr. Hambleton brings extensive clinical oncology drug development and regulatory expertise gained in leadership roles within both the biotechnology and pharmaceutical...
OMO-1 has been evaluated in a monotherapy setting as well as in combination with small molecule EGFR tyrosine kinase inhibitors (TKIs) in Europe, showing a favorable safety profile and early signs of efficacy in MET-selected cancer patients. Allist will drive the clinical development of this...
Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis. A collaboration with MSD will focus on the Phase II evaluation of the combination of BO-112, Highlight’s lead program, and KEYTRUDA®...
Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that it has raised $31 million (€27 million) in a Series A financing round. Vico will use this funding to further advance...
“We progressed from initial compound discovery to the clinic in just two years, and early findings from our first clinical study of CYT-0851 suggest that we will be able to maintain this exceptional momentum,” said Markus Renschler, M.D., Cyteir president and CEO. “We’re excited to...
The grant will be used to hire an Innovation Associate who will work on the implementation of innovative (bio)analytical techniques with high spatial resolution to better understand the microdistribution and local behaviour of CriPec® nanomedicines within the tumour microenvironment (TME)....